Clinical Trial Update: Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating visugromab in combination with immunochemotherapy as first-line treatment for metastatic non-squamous non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-squamous Non-small Cell Lung Cancer

Drugs mentioned

• Visugromab (Visugromab)

Snippet

Sponsor: CatalYm GmbH | Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor | Phase 2 | Status: RECRUITING